Radar · Life Sciences in Watertown
Best Life Sciences Companies in Watertown, United States
The 42 best Life Sciences companies in Watertown, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Neumora.
By Riya SenguptaFinancials
42companies tracked
$3.9Bdisclosed funding
0unicorns
33have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × WATERTOWN
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
150kcombined LinkedIn audience
47%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Watertown
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Neumora Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders | $612M | 46 mo ago | 124 124 → 108 (-13%) | 2020 | Robert Nelsen Co-Founder | — | — |
| 2 | Forma Therapeutics Developer of therapeutic solutions for multiple health purposes | $418M | 80 mo ago | 165 | 2007 | Frank Lee CEO | 996 patents Selective small‑molecule inhibitors of mutant IDH1, CREB/CBP, and USP7/30 enzymes for cancer therapy | — |
| 3 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 14 mo ago | 67 | 2021 | Andrew Schiermeier Chief Executive Officer | — | — |
| 4 | Mariana Oncology Developer of radiopharmaceuticals for solid tumors | $250M | 35 mo ago | 41 41 → 96 (+134%) | 2020 | Simon Read Founder & CEO | 37 patents Peptide-targeted radioligand therapies focusing on DLL3 and B7-H3 cancer antigens | — |
| 5 | Seismic AI-assisted platform for drug discovery and development | $247M | 33 mo ago | 15 | 2019 | Timothy Springer Co-Founder | 47 patents Wearable assistive exosuits for posture correction and biomechanical feedback | — |
| 6 | Affini-T Therapeutics Developer of T-cell therapies against oncogenic driver mutations | $193M | 25 mo ago | 97 | 2020 | Jak Knowles Co-founder | — | — |
| 7 | Selecta Biosciences Developer of nanoparticle immunomodulatory drugs for treating multiple diseases | $155M | 72 mo ago | 67 | 2008 | — | 957 patents Tolerogenic nanocarrier delivery systems for immune‑tolerant therapeutic protein formulations | — |
| 8 | Pandion Therapeutics Developer of therapeutic solutions based on localized immunomodulation | $138M | 77 mo ago | 57 | 2017 | — | — | — |
| 9 | EyePoint Pharmaceuticals Developer of small molecule-based therapeutics for treating ophthalmic disorders | $135M | 67 mo ago | 49 | 1987 | — | 148 patents Biodegradable ocular drug delivery inserts and Tie-2 activating biologic therapeutics. | 1 award |
| 10 | pSivida Drug delivery systems | $128M | 101 mo ago | 49 | 1987 | — | 224 patents Patents concentrated in health & consumer products | — |
| 11 | Syros Pharmaceuticals Developer of small molecule therapeutics for cancer and genetic diseases | $124M | 47 mo ago | 117 | 2012 | Conley Chee CEO | 304 patents Patents concentrated in chemistry & materials | — |
| 12 | Entact Bio Developer of drugs to enhance the functions of beneficial proteins | $121M | 31 mo ago | 32 | 2022 | Sara Buhrlage Founder | — | — |
| 13 | Tarveda Therapeutics Online PG Soft slot platform offering easy-win opportunities and maxwin potential | $119M | 68 mo ago | 31 | 2011 | — | 191 patents Patents concentrated in health & consumer products | — |
| 14 | Sherlock Provider of a diagnostic platform for DNA and RNA detection 62Growth top 13%Funding top 22%Talent top 28%Moat top 41% All 9 signals ▾Growthtop 13% Fundingtop 22% Talenttop 28% Moattop 41% Patentsbottom 46% Innovationbottom 41% Marketbottom 39% Globalbottom 37% Newsbottom 34% Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $111M | 14 mo ago | 33 | 2019 | David Walt Co-Founder | 5 patents Real-time health monitoring and emergency response systems | — |
| 15 | Arkuda Therapeutics Developer of therapeutic solutions for neurological disorders | $108M | 54 mo ago | 28 | 2018 | Duane Burnett Co-Founder | — | — |
| 16 | Corner Therapeutics Developer of immuno-therapeutics to treat cancer 24Funding top 34%Moat top 42%Talent top 45%Global bottom 32% All 5 signals ▾Fundingtop 34% Moattop 42% Talenttop 45% Globalbottom 32% Marketbottom 31% Funding: Raised $105M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $105M | 11 mo ago | 16 16 → 28 (+75%) | 2019 | Andrew Bellinger Co-Founder | — | — |
| 17 | Tectonic Therapeutic Developer of GPCR-targeted therapies | $80M | 18 mo ago | 28 28 → 69 (+146%) | 2019 | — | — | — |
| 18 | Tetraphase Pharmaceuticals US-based, public, clinical-stage biopharma developing tetracycline analogs for multidrug-resistant infections. | $80M | 79 mo ago | 31 | 2006 | — | 237 patents Novel tetracycline antibiotics and their polymorphic/crystalline forms for antimicrobial therapy | — |
| 19 | Progentos Developer of regenerative medicines for multiple sclerosis and other degenerative diseases | $69M | 27 mo ago | — | 2023 | Sanjay Magavi Co-Founder | — | — |
| 20 | Redona Therapeutics Developer of RNA therapeutics to treat cancer and other human diseases | $61M | 37 mo ago | 22 | 2016 | Richard Gregory Co-Founder | — | — |
| 21 | Lyra Therapeutics Biotechnology firm innovating localized therapies for chronic rhinosinusitis (CRS) | $53M | 38 mo ago | 75 | 2005 | George Whitesides Co-Founder | — | — |
| 22 | Zikani Therapeutics Developer of ribosome targeting macrolides | $52M | 77 mo ago | 17 | 2015 | — | — | — |
| 23 | Stellular Bio Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells 37Funding top 28%Talent top 28%Moat bottom 38%Global bottom 37% All 5 signals ▾Fundingtop 28% Talenttop 28% Moatbottom 38% Globalbottom 37% Marketbottom 32% Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $44M | 7 mo ago | 12 | 2014 | Joseph Italiano Co-Founder | — | — |
| 24 | Lexington Medical Abdominal surgical instruments. | $40M | 16 mo ago | 111 | 2013 | Tak Cheung Co-Founder | — | — |
| 25 | Larkspur Developer of immunotherapies to treat cancer | $34M | 39 mo ago | 18 18 → 19 (+6%) | 2020 | Catherine Peyton CEO | 2 patents Automated workout planning and generation systems for personalized fitness programs | — |
| 26 | Enanta Developer of small molecule drugs for infectious and liver diseases | $21M | 155 mo ago | 116 116 → 148 (+28%) | 1998 | Jay Luly CEO | — | 1 partnership |
| 27 | Fluent BioSciences Developer of reagent for DNA analysis for genetic analysis | $19M | 19 mo ago | 48 | 2018 | Sepehr Kiani Founder & CEO & President | 145 patents Microfluidic droplet platforms for high-throughput single-cell and molecular analyses | — |
| 28 | Ingenia Therapeutics Provider of healthcare therapeutic services | $12M | 26 mo ago | — | 2018 | Sangyeul Han Founder & CEO | — | — |
| 29 | EnPlusOne Bio Developer of RNA synthesis platform for gene therapeutics | $12M | 20 mo ago | 9 | 2022 | Daniel Ahlstedt Co-founder and Chief Operating Officer | — | — |
| 30 | Portal Provider of cell engineering and cell analytics across research and clinical applications | $5M | 20 mo ago | — | 2023 | Armon Sharei Founder & CEO | 22 patents AI multi-agent orchestration platform for request routing, verification, and context enrichment | — |
| 31 | PathCision Medicine Developer of targeted therapies for the treatment of metastatic cancer | $2M | 30 mo ago | — | 2022 | David Lee Co-Founder and CSO | — | — |
| 32 | Control Delivery Systems Provider of a drug delivery devices | $690K | 35 mo ago | — | 1998 | Paul Ashton CEO | — | — |
| 33 | Sophia Tree Developer of small molecule therapeutics for oncology | $600K | 44 mo ago | — | 2022 | Shana Wang Co-Founder | — | — |
| 34 | Interactive Motion Robotic help for neurorehabilitation and robotic gym | $300K | 184 mo ago | 8 | 1998 | Neville Hogan Founder | — | — |
Top 12 Life Sciences companies in Watertown
#1
Series A · Watertown, Massachusetts · founded 2014 · 12 employees$44.5Mraised▾
Series A · Watertown, Massachusetts · founded 2014 · 12 employees
Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells. It offers programmable logic controller platform focused on modifying the regenerative power of platelets, enabling researchers to create reengineering cell therapies.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 28%Talent
top 28%Moat
bottom 38%Global
bottom 37%Market
bottom 32%Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) · Last round Series A (Jan 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 883 LinkedIn followers
Funding rounds
- Jan 2026Series A—
- Mar 2025Grant (prize money)$356.5K
- Aug 2019Series A$26.4M
- May 2017Series A$10M
Founders & team
Investors
HHS, BioSciKin, National Heart Lung and Blood Institute, Vivo Capital, Nest Bio Ventures, Cockrell Interests
#2
Series B · Watertown, Massachusetts · founded 2021 · 67 employees$362Mraised▾
Series B · Watertown, Massachusetts · founded 2021 · 67 employees
Developer of next-generation switchable CAR T-cell immunotherapies. This company develops allogeneic platforms to address shortcomings of current T cell-based immunotherapies. Their technology offers powerful controllability of CAR-T reactivity while maintaining high anti-tumor activity. A switchable on/off mechanism, using universal effector cells and soluble adaptors, allows precise targeting of cancer antigens. Rapid switchability lowers the risk of side effects, improving the therapeutic window and safety. The focus is on overcoming limitations of current CAR-T cell therapies.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Moat
top 42%Talent
bottom 49%Market
bottom 45%Global
bottom 45%Tech
bottom 35%Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Grant (prize money) (Jul 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers — 2.8% of this cohort's audience
Funding rounds
- Jul 2025Grant (prize money)$40M
- Oct 2024Series B$112M
- Feb 2023Grant (prize money)$284.1K
- Jun 2021Series A$250M
Founders & team
Investors
Novo Holdings, Blackstone, F-Prime Capital, Eight Roads Ventures, Piper Sandler, NYBC Ventures
Tech stack
Apple Icloud MailCookiebotCore-JsElementorFont AwesomeGodaddy
#3
Series B · Watertown, Massachusetts · founded 2019 · 16 employees$104.9Mraised▾
Series B · Watertown, Massachusetts · founded 2019 · 16 employees
Developer of immuno-therapeutics to treat cancer. It offers a proprietary chemical mimic called dendritic cell hyperactivation, which stimulates protective immunity through the production of polyclonal populations of long-lived memory T cells.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 34%Moat
top 42%Talent
top 45%Global
bottom 32%Market
bottom 31%Funding: Raised $105M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Sep 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated · 1 leadership moves in 12 mo
Audience (LinkedIn): 5k LinkedIn followers — 3.3% of this cohort's audience
Funding rounds
- Sep 2025Series B$16.8M
- Apr 2024Series A$58.5M
- May 2023Series A$58.5M
Founders & team
Investors
Ziff Capital Partners, Cockrell Interests, Tanis Ventures, Sandiaholdings
#4
Acquired · Watertown, Massachusetts · founded 2019 · 33 employees$111Mraised▾
Acquired · Watertown, Massachusetts · founded 2019 · 33 employees
Provider of a diagnostic platform for DNA and RNA detection. The company has developed proprietary CRISPR-based SHERLOCK and synthetic biology-based INSPECTR technologies to create diagnostic tools for the detection of infectious disease, early detection of cancer, treatment monitoring, and precision medicine.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 13%Funding
top 22%Talent
top 28%Moat
top 41%Patents
bottom 46%Innovation
bottom 41%Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo
Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Grant (prize money) (Jun 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Funding rounds
- Jun 2025Grant (prize money)$130.3K
- Aug 2024Grant (prize money)$298.9K
- Jul 2023Grant (prize money)$175K
- Nov 2022Grant (prize money)$2M
Founders & team
Investors
Open Philanthropy, Novalis LifeSciences, Illumina Ventures, Albany Capital, Good Ventures, Northpond Ventures
#5
Public · Watertown, Massachusetts · founded 2019 · 28 employees$80.1Mraised▾
Public · Watertown, Massachusetts · founded 2019 · 28 employees
Developer of GPCR-targeted therapies. The company is developing antibodies and other biologic drugs targeting G protein-coupled receptors. These therapeutics are based on the GEODe platform that targets undruggable receptors.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 3.8% of this cohort's audience
Funding rounds
- Feb 2025Post IPO$185M
- Mar 2021Post IPO$80.1M
Investors
Vida Ventures, Polaris Partners, EcoR1
#6
Late Stage · Watertown, Massachusetts · founded 2013 · 111 employees$40.3Mraised▾
Late Stage · Watertown, Massachusetts · founded 2013 · 111 employees
Lexington Medical, a medical device company, is developing abdominal surgical instruments.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 34k LinkedIn followers — 22.7% of this cohort's audience · 76 engagements/post (1.9× cohort median)
Hiring: 1 hiring post in 12 mo (public)
Activity: 1 product launches announced in 12 mo
Funding rounds
- Apr 2025PE$37.8M
- Mar 2017Conventional Debt$2.5M
Founders & team
Investors
MassDevelopment, Ampersand Capital, Norwich Ventures, LSG Holdings, BAMCAP
Tech stack
BootstrapCloudflareCloudflare Bot ManagementCloudflare Browser InsightsComplianzCore-Js
#7
Series D · Watertown, Massachusetts · founded 2020 · 97 employees$192.6Mraised▾
Series D · Watertown, Massachusetts · founded 2020 · 97 employees
Developer of T-cell therapies against oncogenic driver mutations. The company has a TCR discovery platform that leverages synthetic biology and gene editing technologies to develop therapies for solid tumor cancers. The company has developed therapies targeting oncogenic driver mutations like KRAS and p53.
Funding rounds
- Jul 2024Series D$17.6M
- Mar 2022Series D$175M
- Jul 2020Grant (prize money)$150K
- Apr 2020Grant (prize money)$401.8K
Founders & team
Investors
Fred Hutch, Vida Ventures, Bayer, Humboldt Fund, Catalio Capital Management, Alexandria
Tech stack
Apple Icloud MailBootstrapDiviGodaddyGoogle Font ApiHttp/3
#8
Acquired · Watertown, Massachusetts · founded 2018 · 48 employees$19Mraised▾
Acquired · Watertown, Massachusetts · founded 2018 · 48 employees
Fluent BioSciences is a developer of a proprietary reagent for genetic analysis. The Fluent BioScience’s Pre-templated Instant Partitions (PIPs) enable near-instantaneous self-assembly of individual cells or molecules into uniform partitions. The reagent is used for the preparation of nucleic acids for DNA and RNA sequencing and single-cell molecular analysis.
Funding rounds
- Jan 2025Grant (prize money)$965.6K
- Mar 2022Grant (prize money)$1.7M
- 2020Series A$19M
Founders & team
Investors
NIH SBIR/STTR, Illumina Ventures, Samsara BioCapital, Co-win Ventures, VC23, Civilization Ventures
#9
Series B · Watertown, Massachusetts · founded 2022 · 9 employees$12Mraised▾
Series B · Watertown, Massachusetts · founded 2022 · 9 employees
Developer of RNA synthesis platform for gene therapeutics. It offers ezRNA an enzymatic-based RNA synthesis platform that contains a diverse array of nucleotide modifications for developing RNA therapeutics.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.4% of this cohort's audience
Hiring: 1 hiring post in 12 mo (public) · hiring: Research Associate
Funding rounds
- Dec 2024Series B$10M
- Sep 2022Seed$12M
Founders & team
Investors
Northpond Ventures, Breakout Ventures, Coatue, Camillus LifeSciences
#10
Series B · Watertown, Massachusetts · founded 2019 · 15 employees$247.3Mraised▾
Series B · Watertown, Massachusetts · founded 2019 · 15 employees
AI-assisted platform for drug discovery and development. The platform utilizes machine learning technology to identify and discover protein targets for therapeutic purposes and diseases responsible for adaptive immunity.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 5.4% of this cohort's audience
Funding rounds
- Nov 2023Series B$146.3M
- Feb 2022Series A$101M
Founders & team
Investors
Bessemer Venture Partners, Amgen, Codon Capital, Alexandria, Gaingels, GC&H Investments
#11
Acquired · Watertown, Massachusetts · founded 2020 · 41 employees$250Mraised▾
Acquired · Watertown, Massachusetts · founded 2020 · 41 employees
Developer of radiopharmaceuticals for solid tumors. The company is pioneering a new class of targeted radiopharmaceuticals that are composed of rationally designed conjugates against biological targets, to deliver alpha and beta-emitting radionuclide payloads for oncological diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers — 6.6% of this cohort's audience
Funding rounds
- Sep 2023Series B$175M
- Dec 2021Series A$75M
Founders & team
Investors
Forbion, Deep Track Capital, Atlas Venture, RA Capital Management, Nextech Invest, Citadel
Tech stack
AosApple Icloud MailDocusignGatsbyGodaddyGoogle Analytics
#12
Public · Watertown, Massachusetts · founded 2020 · 124 employees$612Mraised▾
Public · Watertown, Massachusetts · founded 2020 · 124 employees
Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders. The company has developed Data Biopsy Signatures and Precision Phenotypes technologies by using a data-driven neuroscience platform to design targeted therapies for brain diseases. The product pipeline includes NMRA-140, NMRA-511, and NMRA-094 for depressive disorders, anxiety, sleep, and neurodegenerative disorders.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 17k LinkedIn followers — 11.2% of this cohort's audience
Funding rounds
- Oct 2022Series B$112M
- Oct 2021Series A$500M
Founders & team
Investors
Amgen, Arch Venture Partners, F-Prime Capital, ADG, Altitude Life Science Ventures, Exor Ventures
Funding & investor landscape
$3.9Btotal disclosed funding
35companies funded
137disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Joseph Italiano
Co-Founder · Stellular Bio
Jonathan Thon
Founder · Stellular Bio
Andrew Schiermeier
Chief Executive Officer · AvenCell
Andrew Bellinger
Co-Founder · Corner Therapeutics
Jonathan Kagan
Co-Founder & President · Corner Therapeutics
David Walt
Co-Founder · Sherlock
Omar Abudayyeh
Co-Founder · Sherlock
Tak Cheung
Co-Founder · Lexington Medical
Leon Amariglio
Co-Founder & CEO · Lexington Medical
Jak Knowles
Co-founder · Affini-T Therapeutics
Sepehr Kiani
Founder & CEO & President · Fluent BioSciences
Bill Hyun
Founder · Fluent BioSciences
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Breakthroughs are cooling (41%→30% of field), led by Gene.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Advancements are rising (29%→35% of field), led by Gene.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Concerns are cooling (17%→15% of field), led by Agriculture.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
How many Life Sciences companies are there in Watertown, United States?
Radar tracks 42 indexable Life Sciences companies headquartered in Watertown, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Watertown, United States?
The Life Sciences companies in Watertown, United States on this list have raised a combined $3.9B in disclosed equity funding across 35 funded companies.
Which is the highest-funded Life Sciences company in Watertown, United States?
Neumora is the highest-funded Life Sciences company in Watertown, United States, with $612M in disclosed equity funding.
How many Life Sciences companies in Watertown, United States are funded?
35 of the 42 Life Sciences companies in Watertown, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Watertown, United States?
None of the Life Sciences companies in Watertown, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Watertown, United States Life Sciences companies?
The most active investors in Watertown, United States Life Sciences companies on this list include Polaris Partners, HHS, RA Capital Management, Citadel, Flagship Pioneering.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.